Companies: 10,795·Total market cap: $144.5T
Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTXNASDAQHealthcare● Active
$13.55
+$0.29(+2.19%)
Market Cap$258616370
P/E Ratio—
52W High$14.97
52W Low$7.37
Overview

Elicio Therapeutics, Inc. (ELTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001601485 · ELTX · NASDAQ · as of Jun 9, 2026

Filing snapshot

360
Total Filings
10-Q
Latest Form
2026-05-11
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001601485 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-29
Fiscal Year End
Apr 29, 2026
Accession No.
0001601485-26-000035
Primary Document
angn-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001601485 · Accession 0001601485-26-000035

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-11
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-11Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-11
View
8-KCurrent Report
8-K
2026-05-11
View
10-K/AAnnual Report (Amended)
10-K/A
2026-04-29
View
EFFECTEFFECT
EFFECT
2026-03-16
View
8-KCurrent Report
8-K
2026-03-16
View
424B5424B5
424B5
2026-03-16
View
S-8Employee Stock Plan Registration
S-8
2026-03-12
View
CORRESPCORRESP
CORRESP
2026-03-12
View
S-3/AS-3/A
S-3/A
2026-03-12
View
10-KAnnual Report
10-K
2026-03-12
View
8-KCurrent Report
8-K
2026-03-12
View
UPLOADUPLOAD
UPLOAD
2026-03-06
View
S-3/AS-3/A
S-3/A
2026-03-02
View
S-3Shelf Registration
S-3
2026-02-27
View
EFFECTEFFECT
EFFECT
2025-12-03
View
Showing 1–15 of 253 filingsForm 4 / 144 hidden· 360 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001601485  |  Exchange: NASDAQ · Healthcare

Elicio Therapeutics, Inc. (NASDAQ: ELTX) has submitted 360 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001601485, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Elicio Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Elicio Therapeutics, Inc. 10-K was filed on 2026-04-29 for fiscal year ending 2026. Historical ELTX 10-K annual reports are available from 2014 through 2026.

Investors researching Elicio Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
NKTX SEC Filings →MOLN SEC Filings →MIST SEC Filings →CRDF SEC Filings →CRBP SEC Filings →PEPG SEC Filings →SAVA SEC Filings →RANI SEC Filings →
→ ELTX Financials→ ELTX Earnings→ ELTX Insider Trades

Frequently Asked Questions

ELTX SEC Filings · 8 questions

Elicio Therapeutics, Inc. (ELTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 360 filings and access original documents at no cost. Elicio Therapeutics, Inc.'s CIK is 0001601485.

ELTX SEC filingsElicio Therapeutics, Inc. SEC documentsfind ELTX 10-K